Search results
336 results found
Polygenic scores for cancerReportAn overview of what is known about polygenic scores and what they could mean for cancer prediction, prevention and management. A short report for health policy makers and other stakeholders.
CAR-T cell therapy for lupusBlogCAR-T cell therapy involves genetically engineering T cells, a type of immune cell, so that they respond to a prespecified molecular marker, or antigen.
Are data trusts trustworthy?BlogData is vital to health innovation but there remains a common feeling of mistrust in those who hold that data. Dr Elizabeth Redrup Hill considers why and what can be done to engender greater trust.
Are synthetic health data ‘personal data’?ReportCommissioned by the MHRA, we evaluated the current legal framework, regulatory guidance and latest legal commentary to assess whether—or in what circumstances—synthetic health data might be considered ‘personal data’
Evaluation of polygenic risk score applicationsReportHow current evidence is inadequate to determine clinical validity or utility of a polygenic score product in relation to its intended purpose and what is needed to resolve the gaps
Fragmentomics – the future of cfDNA testing?BlogOutlining the work of Prof. Dennis Lo and his team on the emerging science of fragmentomics.
Control of patient information in the COVID-19 eraReportThe ethical and legal considerations that need to be taken into account by policymakers should there be any future extension, or exception for COVID-19 purposes.